Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2020 08:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting

67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...